

## Drug Discovery Toxicology

### ANNUAL REPORT: 2022–2023

May 1, 2022 to April 30, 2023

#### I. Officers/Committees

<b><u>Officer</u></b>	<b><u>2022–2023</u></b>	<b><u>2023–2024</u></b>
President:	Brandon Jeffy	Jonathan Maher
Vice President:	Jonathan Maher	Satoko Kiyota
Vice President-Elect:	Satoko Kiyota	Wenyue Hu
Secretary/Treasurer:	Marianna Stamou	Marianna Stamou
Past President:	Marie Lemper	Brandon Jeffy
Councilors:	Lauren Lewis	Laura Armstrong
Postdoctoral Representative:	Saurabh Vispute	Lauren Lewis
Graduate Student Representative:	Souvarish Sarkar	Dakota Robarts
	Raymond Hau	Zakiyah Henry

#### II. 2022 Membership total: 284

#### III. Key Outcomes in 2022–2023:

##### A. SOT Annual Meeting activities:

- DDTSS was the primary endorser for one workshop and one CE course, and the secondary endorser for one symposium session, one workshop, and another CE course.
- DDTSS hosted a reception at the 2023 SOT Annual Meeting in Nashville, which included an award ceremony for outgoing officers and a session that featured presentations from winners of recent competitions.
- DDTSS hosted a mentoring luncheon.

B. DDTSS hosted a webinar in Q4 2022 (more information below) and circulated a newsletter to the DDTSS membership.

#### IV. Activities

##### A. SOT Annual Meeting Activities (e.g., courses, scientific sessions, receptions):

DDTSS was the primary endorser of the workshop "targeted protein degradation therapeutics: opportunities and challenges" and hosted the CE course "Advanced Discovery Toxicology: Integrating Toxicology with Other Functions on the Team".

DDTSS was the secondary endorser of the symposium "A.I. Buzz or Bliss: Case Studies for a Successful Applications of Artificial Intelligence in Predictive Toxicology", and the symposium "Making the Most of Your Data: How to Build Machine Learning Models for Toxicology", as well as of the CE course "Making the Most of Your Data: How to Build Machine Learning Models for Toxicology" and the workshop "New Approach Methodologies in the Pharmaceutical Sciences: Novel Strategies Challenging the Traditional Testing Paradigm to Increase Regulatory Confidence".

DDTSS hosted a reception (see above) as well as a mentoring luncheon.

B. 2023 Awards Recipients:

**1<sup>st</sup> place Graduate Student Poster Competition**

Enhanced Fetoplacental Cadmium Toxicity in Mice Lacking the Placental Bcrp Transporter, Danielle Kozlosky

**2<sup>nd</sup> place Graduate Student Poster Competition**

Harnessing a Programmable, Microbiome-Based Genome Engineered Live-Biotherapeutic for Sustained Levodopa Delivery in Parkinson's Disease, Piyush Padhi

**3<sup>rd</sup> place Graduate Student Poster Competition**

The Role of Tissue-Restricted FXR Deletion in NASH Development in Mice, Zakiyah Henry

**Paper of the Year Award**

Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys, Tod Harper Jr et al, Tox Sci 2022

C. Other Educational Activities Conducted (e.g., webinars, in-person meetings):

DDTSS hosted a webinar titled "ADME in Liver Disease: Increased Risk of Drug-Induced Toxicity"

November 11, 2022, at 3:00-4:30PM US EST.

The speaker was Dr. Nathan Cherrington, Associate Dean of Research at the University of Arizona.

D. Communication Activities:

1. Newsletter publication frequency: once annually in Q4

2. Communication Highlights:

- Newsletter circulated to the membership in Q4
- New or significant announcements/blogs (e.g. regarding awards, elections or webinars of interest to the membership) were communicated to the membership via e-mail and/or a post on the DDTSS LinkedIn page

3. Highlights of website enhancements: The DDTSS website was maintained and updated as needed.

E. Mentoring Activities: During the SOT Annual Meeting in Nashville, DDTSS hosted a mentoring luncheon for students, postdocs, and early career scientists, where attendees had the opportunity to hear from the DDTSS Officers on their professional experiences in drug discovery toxicology, and get their questions answered regarding careers in drug discovery toxicology.

V. **Feedback and Ideas:**

A. In what ways is your group fostering and maintaining an inclusive environment? Please give examples of any current practices used to support inclusion in processes such as 1) leadership selection and promotion, 2) award descriptions and selection, and 3) endorsement of proposals for the Annual Meetings.

When reviewing applications for awards or session proposals, DDTSS focuses on quality and strength of scientific discussions, but not on demographic aspects (race, ethnicity) based on applicant names and countries. For session proposal review, focus is also placed on assessing whether the array of speakers is diverse enough (gender, race, ethnicity, employment sector, geographic location) to ensure a variety of points of view on the session topic. All SOT/DDTSS members in good membership standing are eligible and encouraged to self-nominate for DDTSS leadership positions.

- B. What is one thing the Society should be doing that we currently do not do (or do not do effectively) that would be of importance/benefit to the members of your component group?

N/A

- C. What is one thing that the Society is currently doing that impacts your component group that should be changed (e.g., stopped, modified, etc.)?

N/A